Adhesion Barrier Market to Skyrocket to Over $550 Million by 2013

Growing interest and innovation will drive adhesion barrier market, according
to Millennium Research Group

WALTHAM, Mass., Feb. 2 /PRNewswire/ -- According to Millennium Research
Group's (MRG's) US Markets for Surgical Hemostats, Internal Tissue Sealants,
and Adhesion Barriers 2009 report, growing surgeon interest in adhesion
barriers, combined with numerous upcoming product launches, will fuel revenues
in the US adhesion barrier market. Exceeding $550 million by 2013, the
adhesion barrier market will experience a compound annual growth rate of
almost 25% over the next five years.

It is estimated that the cost of treating adhesiolysis (the surgical removal
of adhesions) in the US is over $2 billion annually. Due in part to the narrow
range of approved indications for currently available products, the US
adhesion barrier market remains underpenetrated; however, interest in these
products is expanding rapidly as hospitals and surgeons realize the many
benefits of using an adhesion barrier in surgical procedures. This interest
will prompt a growing number of competitors to enter the US adhesion barrier
market in the coming years.

The arrival of new adhesion barriers will expand indications, and the
associated favorable clinical data that supplement product approvals, will
boost surgeon awareness and drive adoption. Improved awareness will further be
bolstered by continuing innovation and intensifying competition from market
competitors, contributing to unit growth and adhesion barrier market expansion
over the next five years.

"Following the removal of Gliatech's ADCON-L, FzioMed's Oxiplex/SP adhesion
barrier was slated to be the first such product approved for spinal
applications in the US," says Kevin Flewwelling, Manager of Orthopedics at
MRG. "But, due to the product's unfavorable approval vote from the FDA's
Orthopaedic & Rehabilitative Devices Panel in July of 2008, several companies
have demonstrated renewed interest in developing an adhesion barrier approved
for use in the lucrative US spine market."

MRG's US Markets for Surgical Hemostats, Internal Tissue Sealants, and
Adhesion Barriers 2009 report provides in-depth coverage of the surgical
hemostat, internal tissue sealant, and adhesion barrier markets. Competitors
covered include Baxter BioSurgery, Covidien, CryoLife, Davol (a subsidiary of
C.R. Bard), Ethicon (a Johnson & Johnson company), Genzyme Biosurgery, King
Pharmaceuticals, MAST Biosurgery, Orthovita, Pfizer, and many more.

About Millennium Research Group
Millennium Research Group (www.MRG.net), a Decision Resources, Inc. company
(www.DecisionResourcesInc.com), is the global authority on medical technology
market intelligence and the leading provider of strategic information to the
health care sector. The company provides specialized industry expertise
through published reports, ongoing Marketrack(TM) projects, and customized
solutions.

About Decision Resources, Inc.
Decision Resources, Inc. is a cohesive portfolio of companies that offers
best-in-class, high-value information, and insights on important sectors of
the health care industry. Clients rely on this analysis and data to make
informed decisions. Please visit Decision Resources, Inc. at
www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be
trademarks or registered trademarks of their respective holders.

For more information, contact:

Amy Krohn
Millennium Research Group
416-364-7776 x101
akrohn@mrg.net

Elizabeth Marshall
Decision Resources Inc.
781-296-2563
emarshall@dresources.com

SOURCE Millennium Research Group

Amy Krohn of Millennium Research Group, +1-416-364-7776 ext. 101,
akrohn@mrg.net; or Elizabeth Marshall of Decision Resources Inc.,
+1-781-296-2563, emarshall@dresources.com